Point of Care testing device for delivery of automated screening for disease via retinal images for worldwide healthcare deployment.

筛查糖尿病视网膜病变（DR）有助于减少糖尿病患者失明的发生率，但只有通过自动化才能实现具有成本效益的筛查规划。为了解决这个问题，Medalytix正在寻求开发一种护理点测试（POCT）设备，通过视网膜图像提供疾病的自动筛查。POCT设备将具有成本效益和便携性，但需要足够的电池电量才能长时间远程工作。该项目的成功将开启在全球范围内提供安全有效的筛查项目的能力，利用英国的技术来解决世界上主要的失明原因（DR和AMD）和世界上主要的死亡原因之一（CVD）。通过在方便的地点（零售/药房/全科医生）提供筛查能力，提高对高危患者的早期发现，将改善患者管理，加快结果和治疗的时间，并最终通过更广泛的人群筛查为医疗保健系统节省成本。研发市场验证补助金将用于与独立的市场和商业化专业公司合作进行正式的市场研究，并将提供所需的资金，帮助Medalytix建立对全球市场的全面验证，全面了解最终用户的需求和要求，并开发一个可靠的商业案例。

Screening for Diabetic Retinopathy (DR) helps reduce the incidence of blindness in peoplewith diabetes, but cost effective screening programmes can only be achieved with automation.To address this Medalytix is looking to develop a Point Of Care Testing (POCT) device fordelivery of automated screening for diseases via retinal images. The POCT device will be costeffectiveand portable but will need sufficient battery power to work remotely for longperiods.Success in the project will open up the ability to deliver safe and effective screeningprogrammes globally, using UK-based technology to address the problem of the world’sleading causes of blindness (DR and AMD) and one of the world’s leading causes of mortality(CVD). Improved early detection of at risk patients through provision of the ability to screenin convenient locations (retail/pharmacy/GP) will allow improved patient management, speedup the time to result and treatment and ultimately deliver cost savings to the healthcare systemvia more widespread screening of the population.The Grant for R&D Proof of Market will be used to work with an independent market andcommercialisation specialist firm for conducting a formal market research and will providethe required funding to help Medalytix establish a full validation of the global market, gaininga thorough understanding of the needs and requirements of end-users and develop a solidbusiness case.